Abstract
Abstract
Background
Evidence showed that Tai Chi may have beneficial effects among hypertensive individuals, although the results are not convincing. We aim to conduct a high-quality clinical trial with 24-h BP measurement to provide robust evidence of Tai Chi for essential hypertension.
Methods
This is an open-label single-center randomized controlled trial with 3 parallel arms. We will compare Tai Chi with walking and waiting-list control. We will recruit 234 hypertensive patients with mild to moderate essential hypertension and randomly assign them to 3 different groups. Participants in Tai Chi group will receive a group-format Yang style 24-form Tai Chi exercise program, 3 sessions per week for 12 weeks. The walking group will be asked to walk, 3 sessions per week for 12 weeks. The waiting-list group will not receive any interventions and/or exercise training. The primary outcome is the change in average 24-h systolic blood pressure (SBP) between baseline and 12 weeks after randomization. The secondary outcomes include 24-h Diastolic Blood Pressure (DBP), average SBP and average DBP during the daytime and night-time, blood pressure (BP) variability, SBP load and DBP load, circadian rhythm of BP, and morning BP surge, endothelial functional indicators, home measured BP, quality of life, adverse events and so on.
Discussion
We expect findings of this trial will provide important insight into application of Tai Chi as an effective and acceptable method for hypertensive patients. Successful completion of this proposed study will also contribute to promotion of Tai Chi in the community in the future.
Trial registration
Clinicaltrials.gov registry: https://clinicaltrials.gov/ct2/show/NCT04267471, date: February 12, 2020.
Funder
Health and Science Research Project of Sichuan Provincial Health Committee
National Major Science and Technology Projects of China
Publisher
Springer Science and Business Media LLC
Subject
Complementary and alternative medicine
Reference51 articles.
1. WHO. Global NCD target: reduce high blood pressure. Geneva: World Health Organization; 2016.
2. WHO. A global brief on hypertension: silent killer, global public health crisis: World Health Day 2013. Geneva: World Health Organization; 2013.
3. WHO. Hypertension prevelance by WHO region. Available from: https://www.who.int/images/default-source/infographics/ncds/prevalence.jpg?sfvrsn=3472e76c_2. Accessed 18 Feb 2020.
4. Wang JG, Li Y. Characteristics of hypertension in the Chinese population. Curr Hypertens Rep. 2012;14(5):410–5.
5. Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, Shao L, Tian Y, Dong Y, Zheng C, Wang J, Zhu M, Weintraub WS, Gao R, China Hypertension Survey Investigators. Status of hypertension in China: results from the China hypertension survey, 2012-2015. Circulation. 2018;137(22):2344–56.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献